MedTrace Logo

Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

NCT04530617 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2021-06-21

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others.

Conditions

Interventions

DRUG

Camostat Mesilate

Tablets

DRUG

Artemisia Annua Leaf

Tea bags

Sponsors & Collaborators

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    lead OTHER

Principal Investigators

  • Jose G Gotes Palazuelos, MD · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-06-10
Completion
2021-06-10

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530617 on ClinicalTrials.gov